ロード中...
Long-Term Safety and Efficacy of Enzyme Replacement Therapyfor Fabry Disease
Elsewhere, we reported the safety and efficacy results of a multicenter phase 3 trial of recombinant human α-galactosidase A (rh-αGalA) replacement in patients with Fabry disease. All 58 patients who were enrolled in the 20-wk phase 3 double-blind, randomized, and placebo-controlled study received s...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
The American Society of Human Genetics
2004
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1182009/ https://ncbi.nlm.nih.gov/pubmed/15154115 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|